Next Article in Journal
Ursolic Acid Inhibits Collective Cell Migration and Promotes JNK-Dependent Lysosomal Associated Cell Death in Glioblastoma Multiforme Cells
Next Article in Special Issue
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
Previous Article in Journal
Protopine/Gemcitabine Combination Induces Cytotoxic or Cytoprotective Effects in Cell Type-Specific and Dose-Dependent Manner on Human Cancer and Normal Cells
Review

Monoclonal Antibodies as Neurological Therapeutics

1
Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece
2
Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece
3
Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France
4
1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece
5
Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece
6
Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece
*
Author to whom correspondence should be addressed.
Academic Editor: Amélia Pilar Rauter
Pharmaceuticals 2021, 14(2), 92; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020092
Received: 20 December 2020 / Revised: 20 January 2021 / Accepted: 22 January 2021 / Published: 26 January 2021
(This article belongs to the Special Issue Monoclonal Antibodies for Migraine Prevention)
Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these diseases. Untangling the molecular mechanisms of disease allows monoclonal antibodies to block disease pathways accurately and efficiently with exceptional target specificity, minimizing non-specific effects. On the other hand, accumulating experience shows that monoclonal antibodies may carry class-specific and target-associated risks. This article provides an overview of different types of monoclonal antibodies and their characteristics and reviews monoclonal antibodies currently in use or under development for neurological disease. View Full-Text
Keywords: monoclonal antibodies; multiple sclerosis; migraine; neuromyelitis optica spectrum disorder; myasthenia gravis; Alzheimer’s disease; inflammatory myopathies; immune-mediated peripheral neuropathies; Parkinson’s disease; neurooncology; Duchene’s muscular dystrophy monoclonal antibodies; multiple sclerosis; migraine; neuromyelitis optica spectrum disorder; myasthenia gravis; Alzheimer’s disease; inflammatory myopathies; immune-mediated peripheral neuropathies; Parkinson’s disease; neurooncology; Duchene’s muscular dystrophy
Show Figures

Figure 1

MDPI and ACS Style

Gklinos, P.; Papadopoulou, M.; Stanulovic, V.; Mitsikostas, D.D.; Papadopoulos, D. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals 2021, 14, 92. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020092

AMA Style

Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals. 2021; 14(2):92. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020092

Chicago/Turabian Style

Gklinos, Panagiotis, Miranta Papadopoulou, Vid Stanulovic, Dimos D. Mitsikostas, and Dimitrios Papadopoulos. 2021. "Monoclonal Antibodies as Neurological Therapeutics" Pharmaceuticals 14, no. 2: 92. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14020092

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop